XSHG
603585
Market cap369mUSD
Jul 10, Last price
9.36CNY
1D
-4.33%
1Q
-58.86%
Jan 2017
-76.01%
IPO
-60.60%
Name
Suli Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Suli Co., Ltd., based in Jiangyin, China, operates as a chemical manufacturer engaged in the research, production, and sale of a diverse range of fine chemicals. Their product portfolio encompasses agrochemicals, flame retardants, and pharmaceutical intermediates. Within agrochemicals, the company provides technical-grade active ingredients like chlorothalonil, azoxystrobin, diflubenzuron, fluazinam, cymoxanil, and boscalid, along with various prepared pesticide formulations. For flame retardants, Suli produces decabromodiphenyl ethane, in addition to offering brominated, environmentally friendly, and halogen-free options. Their extensive list of chemical intermediates includes compounds such as trichloroacetonitrile, tetrachlorophthalonitrile, pentachloropyridine, pentachlorobenzonitrile, isophthalodinitrile, hydrobromic acid, 1,2-diphenylethane, and 1,2-dibromoethane. Furthermore, the company manufactures industrial biocides under the "Longee" brand, featuring products like 985CHL, 550CCD, 550CC, and 500CHL. They also supply a ferric chloride solution, primarily utilized for water treatment. These products, sold under the "Suli" brand, cater to a variety of industries, including agricultural production, plastics manufacturing, and building materials. Suli Co., Ltd. maintains a significant global presence, distributing its goods across the European Union, North America, South America, Africa, Southeast Asia, and other international markets.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||